摘要
Objective: We compared drug delivery efficiency among intracalvarial bone marrow administration (ICO), intrathecal administration (ICA), and intranasal administration (INA). We also compared the therapeutic effects of Y-3 solution delivered by these three routes in a mouse model of permanent middle cerebral artery occlusion (pMCAO).
Methods: Male mice were randomly assigned to an untreated control group or to the ICO-EB, ICA-EB, or INA-EB group. At 10, 30, and 60 min after administration, EB concentrations in different tissues were determined by measuring the optical density of tissue homogenates at 610 nm with a multimode microplate reader.
For the pMCAO experiment, male mice were randomly assigned to the sham-operated, model, ICO-Y3, ICA-Y3, or INA-Y3 group. Starting 1 h after the onset of cerebral ischemia, the ICO-Y3, ICA-Y3, and INA-Y3 groups received 5 μL of Y-3 solution (2 mg/mL) via their respective routes once daily for 7 days. Neurological function was assessed on days 1, 3, 5, and 7 after ischemia using the modified neurological severity score (mNSS). Cerebral infarct volume was assessed on day 7 after ischemia by staining with 2,3,5-triphenyltetrazolium chloride (TTC).
Results: Cerebral cortical EB concentrations tended to decrease from 10 to 60 min after administration in the ICA-EB and INA-EB groups. In the ICA-EB group, concentrations at 10, 30, and 60 min were 12.04 ± 8.23, 11.55 ± 2.94, and 4.16 ± 2.37 μg/mL, respectively (p = 0.980 for 10 vs. 30 min and p = 0.016 for 30 vs. 60 min). In the INA-EB group, the corresponding values were 16.52 ± 1.19, 8.20 ± 0.82, and 4.84 ± 6.28 μg/mL (p = 0.030 and p = 0.005, respectively). In the ICO-EB group, concentrations tended to increase, with corresponding values of 50.92 ± 2.99, 52.33 ± 9.96, and 53.89 ± 11.52 μg/mL (p = 0.993 and p = 0.580, respectively).
At 60 min, the cerebral cortical EB concentration was significantly higher in the ICO-EB group than in the ICA-EB group (53.89 ± 11.52 vs. 4.15 ± 2.37 μg/mL, P < 0.001) and the INA-EB group (53.89 ± 11.52 vs. 4.59 ± 1.11 μg/mL, P < 0.001), with FAB = 2.666. At 60 min after intracalvarial bone marrow administration, the highest EB concentration among brain regions was found in the cerebellum (63.55 ± 11.94 μg/mL), followed by the cerebral cortex (53.89 ± 11.52 μg/mL), hippocampus (53.02 ± 5.94 μg/mL), and basal ganglia (40.83 ± 12.03 μg/mL).
On day 7 after cerebral ischemia, the ICO-Y3 group had lower mortality (40% vs. 60%), better neurological scores (8.60 ± 1.14 vs. 14.86 ± 1.07, p < 0.001), and smaller cerebral infarct volumes (28.07 ± 4.92 vs. 38.62 ± 6.18 mm3, p = 0.004) than the model group.
Conclusion: Compared with ICA and INA, ICO achieved higher drug delivery efficiency and showed greater therapeutic efficacy in the mouse model of ischemic stroke. ICO may offer a new approach to treating cerebral ischemia.
Keywords: ischemic brain injury, intracalvarial bone marrow administration, intrathecal administration, intranasal administration
